3-羟基-环戊酮乙烯缩醛 | 109459-57-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-羟基-环戊酮乙烯缩醛
• 英文名称: 3-hydroxy cyclopentanone acetal
• 英文别名: 3-hydroxy-cyclopentanone ethylene acetal；1,4-dioxaspiro[4.4]nonan-7-ol；1,4-dioxaspiro[4.4]nonan-8-ol
• CAS: 109459-57-6
• 化学式: C₇H₁₂O₃
• 分子量: 144.17
• InChiKey: GIFUGOIZRIPGPS-UHFFFAOYSA-N

物化性质

• 沸点：
  100 °C(Press: 4 Torr)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-羟基-环戊酮乙烯缩醛 在 吡啶 、 chromium(III) oxide 、 kieselguhr 作用下， 以 二氯甲烷 为溶剂， 反应 0.33h， 以85%的产率得到1,4-二氧杂螺[4.4]壬烷-7-酮
  参考文献：
  名称：

  锌-氯三甲基硅烷和氢化铝锂的区域选择性还原2,3-环氧乙缩醛：1,2和1,3-二酮的方便合成

  摘要：

  已经发现各种2，3-环氧乙缩醛用锌-氯代三甲基硅烷和氢化铝锂进行区域选择性还原，分别得到2-羟基和3-羟基乙缩醛。它们的氧化然后水解，以良好的产率提供了相应的1，2-和1，3-二酮。

  DOI：

  10.1016/s0040-4039(00)95779-4
• 作为产物：
  描述：

  2-环戊烯-1-酮缩乙醛 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 三正丁基氢锡 作用下， 以 水 、 二甲基亚砜 、 苯 为溶剂， 反应 2.0h， 生成 3-羟基-环戊酮乙烯缩醛
  参考文献：
  名称：

  有机合成中的手性缩醛：从2,3-烯烃缩醛区域选择性合成2和3-羟基缩醛。再调查和进一步申请

  摘要：

  通过LAH还原相应的环氧化物和通过溴代醇，然后分别通过TBTH还原，将非手性以及手性的2，3-烯烃缩醛转化为2-和3-羟基缩醛。描述了1，3-二酮的合成。来自手性体系的化合物进一步用于不对称合成。

  DOI：

  10.1016/s0040-4020(01)85714-8

文献信息

• [EN] HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULATEURS DE FXR (NR1H4) CONTENANT DES GROUHYDROXY
  申请人：GILEAD SCIENCES INC

  公开号：WO2016096115A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds (1) which bind to the NR1 H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds (1) for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及结合NR1 H4受体（FXR）并作为FXR激动剂的化合物（1）。本发明还涉及利用这些化合物（1）制备药物以治疗疾病和/或病况，通过这些化合物结合所述核受体，并涉及这些化合物的合成过程。
• [EN] INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS<br/>[FR] DÉRIVÉS D'INDOLE ET DE BENZOMORPHOLINE EN TANT QUE MODULATEURS DES RÉCEPTEURS MÉTABOTROPIQUES DU GLUTAMATE
  申请人：ORTHO MCNEIL JANSSEN PHARM

  公开号：WO2010043396A1

  公开（公告）日：2010-04-22

  The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及新颖化合物，特别是根据式(I)的新型吲哚和苯并吗啡啉衍生物，其中所有基团如申请和索赔中所定义。根据本发明的化合物是代谢型受体-亚型2（"mGluR2"）的阳性变构调节剂，对于治疗或预防与谷氨酸功能障碍相关的神经和精神障碍以及涉及代谢型受体中mGluR2亚型的疾病是有用的。特别是，这些疾病是来自焦虑、精神分裂症、偏头痛、抑郁症和癫痫的中枢神经系统疾病。该发明还涉及制备这种化合物和组合物的药物组合物和过程，以及利用这种化合物预防和治疗涉及mGluR2的这些疾病。
• INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Cid-Nunez Jose Maria

  公开号：US20110275624A1

  公开（公告）日：2011-11-10

  The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

  本发明涉及一种新型化合物，特别是根据公式（I）中定义的所有基团的新型吲哚和苯并吗啡衍生物。本发明的化合物是代谢型受体亚型2（“mGluR2”）的正向变构调节剂，可用于治疗或预防与谷氨酸功能障碍有关的神经和精神障碍以及涉及代谢型受体亚型2的疾病。特别是，这些疾病是从焦虑、精神分裂症、偏头痛、抑郁症和癫痫等中枢神经系统疾病中选择的。本发明还涉及制备这种化合物和组合物的制药组合物和制备过程，以及使用这种化合物预防和治疗涉及mGluR2的这些疾病。
• HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS
  申请人：Gilead Sciences, Inc.

  公开号：US20160176861A1

  公开（公告）日：2016-06-23

  The present invention relates to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The invention further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

  本发明涉及与NR1H4受体（FXR）结合并作为FXR激动剂的化合物。本发明进一步涉及利用这些化合物制备药物，通过这些化合物与该核受体结合治疗疾病和/或病况，以及制备这些化合物的合成过程。
• VANKAR YASHWANT D.; CHAUDHURI NARAYAN C.; RAO C. TRINADHA, TETRAHEDRON LETT., 28,(1987) N 5, 551-554
  作者：VANKAR YASHWANT D.、 CHAUDHURI NARAYAN C.、 RAO C. TRINADHA

  DOI：——

  日期：——